Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2021 | ESAs for the management of lower-risk MDS

Sophie Park, MD, Grenoble Alpes Hospital, Grenoble, France, discusses the use of erythropoietin-stimulating agents (ESAs) for the management of lower-risk myelodysplastic syndromes (MDS), outlining key studies of interest. Prof. Park discusses the EMA approval of epoetin alfa in patients with lower-risk MDS, as well as the variety of ESAs which are currently under investigation and the optimal use of ESAs to maximize response rate. This interview took place at the 16th International Congress on Myelodysplastic Syndromes, held virtually in 2021.

Disclosures

Sophie Park, MD, has participated in advisory boards with Novartis, Pfizer, Takeda, and BMS/Celgene; has received research grants from Novartis, Pfizer, Takeda, BMS/Celgene and Sandoz; and has received speaker’s honoraria from Novartis, Takeda ad BMS/Celgene.